Clinical trial
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without…
NCT01272037 · National Cancer Institute (NCI), NIH · Active, not recruiting
Key facts
| NCT number | NCT01272037 |
|---|---|
| Title | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer |
| Official title | A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine… |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma |
| Intervention type | Drug, Other |
| Interventions | Anastrozole, Exemestane, Laboratory Biomarker Analysis, Letrozole, Quality-of-Life Assessment, Systemic Chemotherapy, Tamoxifen Citrate |
| Enrollment | 5,018 |
| Start date | Jan 15, 2011 |
| Primary completion | Feb 1, 2023 |
| Completion | Oct 1, 2032 |
| First posted | Jan 7, 2011 |
| Last update posted | Nov 25, 2025 |
| Countries | Canada, Colombia, France, Ireland, Mexico, Puerto Rico, Saudi Arabia, South Korea, Spain, United States |
At a glance
- 1,000+ Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: